Patent US4831057A successfully refreshed from Google Patents.
US4831057A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antisnoring agent
Assignee: Individual
•
Filing: 1987-04-27
•
Granted: 1989-05-16
•
Expires: 2007-04-27
Abstract
Abstract Antisnoring agent for oral or local application in the nasal/pharyngal cavities comprising an active content of a secretolytically and/or secretoproductively effective substance, as the active ingredient, together with carrier substances for diluents which are compatible with mucous membranes.
Inventors
- 👤 Dietrich Reichert
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 18:28
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K31/185; A61K31/19; A61K31/195
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
43 words
The method for substantially reducing or eliminating snoring in humans, comprising the step or orally administering to humans afflicted with snoring, a composition containing a therapeutically effective amount of ambroxol in a dose of from 30 to 100 mg in a suitable carrier.
Claim 2
Independent Claim
43 words
The method for substantially reducing or eliminating snoring in humans, comprising the step or orally administering to humans afflicted with snoring, a composition containing a therapeutically effective amount of ambroxol in a dose of from 30 to 100 mg in a suitable carrier.
Claim 3
Independent Claim
48 words
The method for substantially reducing or eliminating snoring in humans, comprising the step of topically applying to the nasopharyngeal mucous membranes of humans afflicted with snoring, a composition comrising a therapeutically effective amount of ambroxol in a dose of from 30 to 100 mg in a suitable carrier.
Claim 4
Independent Claim
48 words
The method for substantially reducing or eliminating snoring in humans, comprising the step of topically applying to the nasopharyngeal mucous membranes of humans afflicted with snoring, a composition comrising a therapeutically effective amount of ambroxol in a dose of from 30 to 100 mg in a suitable carrier.
References Cited (Backward Citations)
GB2101485A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-05-15 | 1992-11-14 | 1993-05-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-05-15 | 1996-11-14 | 1997-05-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-05-15 | 2000-11-14 | 2001-05-16 | $7700.00 | Window Closed / Lapsed |